<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019679</url>
  </required_header>
  <id_info>
    <org_study_id>GaziosmanpasaU</org_study_id>
    <nct_id>NCT03019679</nct_id>
  </id_info>
  <brief_title>Serum Endocan Levels in Polycystic Ovary Syndrome</brief_title>
  <official_title>Serum Endocan Levels in Polycystic Ovary Syndrome: a Possible Marker of Angiogenic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokat Gaziosmanpasa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokat Gaziosmanpasa University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aimed to investigate whether there is a relation between&#xD;
      polycystic ovary syndrome and serum endocan levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome is a disorder which is associated with insulin resistance,&#xD;
      diabetes, obesity, and cardiovascular disease. Endothelial dysfunction, which is known to be&#xD;
      an early marker of atherosclerosis, has also been shown to have an association with poycystic&#xD;
      ovary syndrome. In this study the investigators aimed to investigate whether there is a&#xD;
      relation between polycystic ovary syndrome and serum endocan levels. For this purpose the&#xD;
      investigators designed a prospective study including two groups. The diagnosis of polycystic&#xD;
      ovary syndrome was made in the presence of ;oligo- and/or anovulation,clinical&#xD;
      hyperandrogenism and polycystic ovaries. Clinical hyperandrogenism was defined by the&#xD;
      presence of hirsutism , acne, or the presence of androgenic alopecia, body mass index (BMI)&#xD;
      was calculated as weight in kilograms divided by the square of height in meters. The two&#xD;
      groups are compared considering their serum endocan levels,follicle stimulating hormone&#xD;
      (FSH), luteinizing hormone (LH), Dihydroepiandesterone sulphate (DHEAS), total testesterone&#xD;
      (TT), estradiol (E2) and thyroid stimulating hormone (TSH), fasting blood glucose,&#xD;
      triglyceride, total cholesterol, high density lipoprotein, low density lipoprotein, and&#xD;
      C-reactive protein (CRP) levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum endocan level and its relationship with Polycystic Ovary Syndrome</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">175</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Patients with polycystic ovary syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients without polycyctic ovary syndrome</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples,centrifuged&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        84 women with PCOS and 84 healty women as control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 45 years&#xD;
&#xD;
          -  Patients diagnosed with PCOS according to Rotterdam criteris (for the study group)&#xD;
&#xD;
          -  Patients without PCOS and menstrual irregularities (for the control group)&#xD;
&#xD;
          -  Absence of significant abnormalities on physical examination except hirsutism&#xD;
&#xD;
          -  No lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy&#xD;
&#xD;
          -  Normal thyroid function and prolactin level&#xD;
&#xD;
          -  Absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic&#xD;
             disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Ovarian tumors&#xD;
&#xD;
          -  Endocrine diseases (Cushing disease, 21-Hydroxylase enzyme deficiency, thyroid&#xD;
             dysfunction,hyperprolactinemia,diabetes)&#xD;
&#xD;
          -  Chronic diseases (renal insufficiency, cardiovascular, hepatic disease)&#xD;
&#xD;
          -  Oral contraceptive use, anti-androgenic,glucocorticoid, anti-hypertansive-&#xD;
             anti-diabetic drug use&#xD;
&#xD;
          -  Smoking or alcohol use&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilhan B Delibas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gaziosmanpasa University Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esra Laloglu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Erzurum Halk Saglıgı Laboratuvarı</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gaziosmanpasa University</name>
      <address>
        <city>Tokat</city>
        <zip>60000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokat Gaziosmanpasa University</investigator_affiliation>
    <investigator_full_name>İlhan Bahri Delibas</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

